"Background: Sjögren’s syndrome (SS) is a progressive autoimmune disease characterized by local mononuclear cell infiltration of the salivary and lachrymal glands. Labial biopsy demonstrates local infiltration by Th1 cells that produce pro-inflammatory cytokines, such as interleukin-2 (IL2). The aim of this study was to assess the utility of 99mTc-labelled-IL2 (99mTc-IL2) in evaluating in vivo the extent and severity of lympho-mononuclear cell infiltration in the salivary glands of patients with SS.

"Background: Venous thromboembolism (VTE) is a common disease in Latin American settings. Implementation of international guidelines in Latin American settings requires additional considerations. Objective: To provide evidence-based guidelines about VTE prevention for Latin American patients, clinicians, and decision makers. Conclusions: This guideline ADOLOPMENT project highlighted the importance of contextualization of recommendations in other settings, based on differences in values, resources, feasibility, and health equity impact."

"Background: From 2017 to 2020, the American Society of Hematology (ASH) collaborated with 12 hematology societies in Latin America to adapt the ASH guidelines on venous thromboembolism (VTE).

"Jimenez-Alvarez LF, Reyes LP, Alvarez-Moreno CA, Gomez K, Alarcon J, Oñate JM, Aguilar-Moreno LA, Bravo-Ojeda JS, Gutierrez-Tobar IF." 29/12/2022

"Jimenez-Alvarez LF, Reyes LP, Alvarez-Moreno CA, Gomez K, Alarcon J, Oñate JM, Aguilar-Moreno LA, Ojeda JSB, Tobar IFG." 5/10/2022

Background
The International Nosocomial Infection Control Consortium (INICC) has found a high ICU mortality rate in Latin America.                                                                                   

Jiménez-Alvarez LF, Gomez-Nieto K, Aguilar-Moreno LA. 06/09/2022

Background
The International Nosocomial Infection Control Consortium has found a high ICU mortality rate. Our aim was to identify all-cause mortality risk factors in ICU-patients.

Bass AD, Arroyo R, Boster AL, Boyko AN, Eichau S, Ionete C, Limmroth V, Navas C, Pelletier D, Pozzilli C, Ravenscroft J, Sousa L, Tintoré M, Uitdehaag BMJ, Baker DP, Daizadeh N, Choudhry Z, Rog D; 24/12/2020

Background
Alemtuzumab significantly improved clinical and MRI outcomes vs. subcutaneous interferon beta-1a (SC IFNB-1a) in the CARE-MS trials (NCT00530348, NCT00548405), with sustained efficacy in 2 consecutive extensions (NCT00930553, NCT02255656 [TOPAZ]).

Combariza JF, Arango M, Díaz L, et al. 14/11/2020

Abstract
Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic leukemia (ALL) is the strongest predictor of hematologic relapse. The objective of the study was to assess disease-free survival (DFS) and overall survival (OS) of patients with ALL according with MRD status at the end of induction therapy in a Colombian population.

Agudelo C, 14/12/2021

Combariza JF, Ordúz R, Agudelo C, Hernandez S, Madera AM, León G, Avila V,Bautista L, Valdés J, Camargo C, Sanchez V, Mejía F, Moreno L, Ramirez C. 26/02/2022